Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug hopes to restore arm function after spinal cord injury

NCT ID NCT04295538

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called elezanumab in people with a recent cervical spinal cord injury. The goal was to see if the drug could improve arm and hand movement and was safe. About 60 adults aged 18-75 with severe neck-level injuries received either the drug or a placebo within 24 hours of injury and then every 4 weeks for nearly a year. The study is complete, and results will show if elezanumab helps nerve recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

60 people

The number who actually took part.

Started

Sep 2020

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Acute traumatic cervical spinal cord injury (SCI), neurological level of injury of C4, C5, C6, or C7 with no damage to cord in thoracic (T2 and beyond) and lumbar regions that, in the investigator's opinion, would significantly limit recovery. * Maximum screening UEMS of 32. * American Spinal Injury Association Impairment Scale (AIS) grade A or B at Screening. * Able to initiate study drug administration within 24 hours of injury. * Participants with comorbid conditions that, in the investigator's opinion, are clinically stable and not expected to meaningfully progress in the following 12 months, may be considered eligible to participate. Exclusion Criteria: * Evidence of complete spinal cord transection. * Significant concomitant head injury with a clinically significant abnormality on a head computed tomography (CT). * One or more upper extremity muscle groups untestable (e.g., immobilized or restricted by a cast) during the screening International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) examination. * Known receipt of any other investigational product within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study. * Female who is pregnant, breastfeeding, or considering becoming pregnant during the study or for within 39 weeks (5 half-lives) after the last dose of study drug. * The cause of the acute SCI is one of the following: from gunshot or penetrating/stab wound; non-traumatic SCI, results of seizure, or known attempted suicide.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spinal cord injury(SCI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

spinal cord injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spinal cord injury(SCI)

Contacts and locations

Locations

  • Ajou University Hospital /ID# 241119

    Suwon, Gyeonggido, 16499, South Korea

  • Beth Israel Deaconess Medical Center /ID# 218149

    Boston, Massachusetts, 02215-5400, United States

  • Brigham & Women's Hospital /ID# 216342

    Boston, Massachusetts, 02115, United States

  • CIUSSS du Nord-de-l'ile-de-Montréal_Hopital du Sacré-Coeur de Montréal /ID# 215210

    Montreal, Quebec, H4J 1C5, Canada

  • Complejo Hospitalario Universitario A Coruña /ID# 216384

    A Coruña, A Coruna, 15006, Spain

  • Duplicate_Boston University School of Medicine /ID# 218371

    Boston, Massachusetts, 02118-2515, United States

  • Duplicate_Duke Cancer Center /ID# 216888

    Durham, North Carolina, 27710-3000, United States

  • Duplicate_Inha University Hospital /ID# 238890

    Junggu, Incheon Gwang Yeogsi, 22332, South Korea

  • Duplicate_Tufts Medical Center /ID# 225410

    Boston, Massachusetts, 02111, United States

  • Foothills Medical Centre /ID# 214790

    Calgary, Alberta, T2N 2T9, Canada

  • Funabashi Municipal Medical Center /ID# 225599

    Funabashi-shi, Chiba, 273-8588, Japan

  • Hackensack Univ Med Ctr /ID# 215754

    Hackensack, New Jersey, 07601, United States

  • Hospital Nacional de Paraplejicos /ID# 225508

    Toledo, 45071, Spain

  • Hospital Universitario 12 de Octubre /ID# 225354

    Madrid, 28041, Spain

  • Hospital Universitario Vall de Hebron /ID# 217794

    Barcelona, 08035, Spain

  • Hospital Universitario Virgen del Rocio /ID# 225692

    Seville, 41013, Spain

  • Hospital Universitario y Politecnico La Fe /ID# 217797

    Valencia, 46026, Spain

  • Japan Organization of Occupational Health and Safety Spinal Injuries Centre /ID# 224141

    Iizuka-shi, Fukuoka, 820-8508, Japan

  • Jersey Shore University Medical Center /ID# 218162

    Neptune City, New Jersey, 07753-4859, United States

  • NHO Nagoya Medical Center /ID# 239617

    Nagoya, Aichi-ken, 460-0001, Japan

  • National Hospital Organization Murayama Medical Center /ID# 223492

    Musashimurayama-shi, Tokyo, 2080011, Japan

  • Northwestern University Feinberg School of Medicine /ID# 218009

    Chicago, Illinois, 60611-2927, United States

  • Oregon Medical Research Center /ID# 227371

    Portland, Oregon, 97239, United States

  • QEII - Health Sciences Centre /ID# 215249

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • Regents of the University of Michigan /ID# 215890

    Ann Arbor, Michigan, 48109-1276, United States

  • Royal Adelaide Hospital /ID# 216953

    Adelaide, South Australia, 5000, Australia

  • Rutgers New Jersey School of Medicine /ID# 216212

    Newark, New Jersey, 07103, United States

  • Sentara Norfolk General Hospital /ID# 218302

    Norfolk, Virginia, 23507, United States

  • Shepherd Center, Inc /ID# 230370

    Atlanta, Georgia, 30309-1426, United States

  • The Chaim Sheba Medical Center /ID# 240917

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The Ottawa Hospital Civic Campus /ID# 215270

    Ottawa, Ontario, K1Y 4E9, Canada

  • Thomas Jefferson University Hospital /ID# 215460

    Philadelphia, Pennsylvania, 19107, United States

  • Toronto Western Hospital /ID# 215214

    Toronto, Ontario, M5T 2S8, Canada

  • University of California Davis Health /ID# 224892

    Sacramento, California, 95817, United States

  • University of Louisville Hospital /ID# 215948

    Louisville, Kentucky, 40202, United States

  • University of Pennsylvania /ID# 218662

    Philadelphia, Pennsylvania, 19104-5502, United States

  • University of Virginia Health /ID# 218117

    Charlottesville, Virginia, 22908, United States

  • Virginia Commonwealth University Medical Center Main Hospital /ID# 217481

    Richmond, Virginia, 23219, United States

  • Washington University-School of Medicine /ID# 215325

    St Louis, Missouri, 63110, United States

  • West Virginia University Hospitals /ID# 217344

    Morgantown, West Virginia, 26506, United States

  • Wisconsin Medical Center /ID# 215610

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.